Preferences for Certainty Versus Access When Evaluating New Cancer Drugs. A Discrete Choice Experiment.

Cancer Clinical Trial

Official title:

Preferences of Individuals in the United States With Personal Experience of Cancer for Certainty Versus Access When Evaluating New Cancer Drugs. A Discrete Choice Experiment.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05936632
• Other study ID #: 213621
• Status: Completed
• Start date: July 7, 2023
• Est. completion date: July 20, 2023

Study information

• Verified date: June 2024
• Source: London School of Economics and Political Science
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To provide timely access to new treatments, some eligible drugs can be approved despite uncertainty surrounding the level of clinical benefit they offer patients.

It is not currently known if (and under which circumstances) people would prefer to wait to access some new drugs in exchange for greater certainty surrounding their clinical benefit.

This study aims to elicit the preferences of people in the US with experience of cancer for wait times and clinical uncertainty of new drugs.

To elicit this information, in a survey format, respondents will be presented with a hypothetical scenario and asked to state their preferences for new treatments, each with different attributes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 998
• Est. completion date: July 20, 2023
• Est. primary completion date: July 20, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Individuals previously or currently diagnosed with any type of cancer.

• Individuals with immediate family members previously or currently diagnosed with any type of cancer.

Exclusion Criteria:

• Individuals without previous or current diagnosis with any type of cancer (themselves or immediate family members).

Related Conditions & MeSH terms

• Cancer

Intervention

Other:
• Discrete Choice Experiment (DCE)
DCE survey experiment

Locations

Country	Name	City	State
United Kingdom	London School of Economics	London

Sponsors (1)

Lead Sponsor	Collaborator
London School of Economics and Political Science

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Preferences for treatment attributes and trade-offs between attributes.	Preferences for different treatment attributes (including clinical uncertainty and wait time), and trade-offs between these, using a study-specific Discrete Choice Experiment (DCE) Questionnaire. Preferences are measured on relative utility scale (arbitrary units, no min/max). Utility indicates preference e.g., higher values are more preferred (better).	Through study completion, an average of 4-8 weeks.